AZ505: Potent and Selective SMYD2 Inhibitor for Epigenetic Regulation Research

Executive Summary: AZ505 is a potent and substrate-competitive SMYD2 inhibitor with an IC₅₀ of 0.12 μM, developed and supplied by APExBIO [product page]. It selectively inhibits SMYD2, a protein lysine methyltransferase involved in histone and non-histone methylation, impacting gene transcription and disease processes such as cancer and fibrosis (Chen et al., 2023). AZ505 displays minimal off-target activity against other methyltransferases (IC₅₀ > 83.3 μM for SMYD3, DOT1L, EZH2), and demonstrates efficacy in renal fibrosis and cancer models. Researchers use AZ505 to dissect the histone methylation pathway, optimize epigenetic regulation workflows, and study disease mechanisms where SMYD2 is dysregulated.

Biological Rationale

SMYD2 (SET and MYND domain-containing protein 2) is a lysine methyltransferase that catalyzes mono- and di-methylation of lysine residues on histones H3 (K36) and H4, as well as non-histone substrates such as p53 and retinoblastoma protein (Rb) (Chen et al., 2023). Methylation by SMYD2 regulates gene expression, cell cycle, and apoptosis. Overexpression of SMYD2 has been observed in several cancers, including gastric cancer and esophageal squamous cell carcinoma (ESCC), where it drives tumorigenesis and disease progression. In chronic kidney disease (CKD), SMYD2 activity is associated with renal fibrosis, epithelial-mesenchymal transition (EMT), and inflammation. Pharmacological inhibition of SMYD2 has emerged as a promising strategy to modulate epigenetic regulation in cancer biology and fibrotic disease models.

Mechanism of Action of AZ505, a potent and selective SMYD2 inhibitor

AZ505 is a small molecule inhibitor that binds competitively to the peptide substrate binding groove of SMYD2. Unlike co-factor competitive inhibitors, AZ505 does not compete with S-adenosylmethionine (SAM) but blocks substrate access, preventing SMYD2-mediated methylation. The compound exhibits an IC₅₀ of 0.12 μM and a K_i of 0.3 μM for SMYD2 enzymatic assays. Selectivity profiling shows negligible inhibition of closely related methyltransferases, including SMYD3, DOT1L, and EZH2, at concentrations up to 83.3 μM. Structural studies confirm that AZ505 occupies the substrate binding groove, providing high specificity and minimal off-target effects. For optimal solubility, AZ505 is dissolved in DMSO and may require warming to 37°C and ultrasonic agitation prior to use. The compound is stable when stored at -20°C. These properties enable researchers to interrogate the functional consequences of substrate-competitive SMYD2 inhibition in vitro and in vivo (APExBIO product documentation).

Evidence & Benchmarks

• AZ505 inhibits SMYD2 enzymatic activity with an IC₅₀ of 0.12 μM under standard assay conditions (pH 7.5, 25°C, using histone H3 peptide substrate) (APExBIO).
• AZ505 demonstrates high selectivity for SMYD2 over SMYD3, DOT1L, and EZH2, with IC₅₀ values exceeding 83.3 μM for these off-targets (APExBIO).
• In cisplatin-induced chronic kidney disease mouse models, AZ505 treatment significantly reduced SMYD2 expression, renal fibrosis, and inflammatory cytokine levels (e.g., IL-6, TNF-α) (Chen et al., 2023).
• AZ505 suppressed phosphorylation of Smad3 and STAT3, key signaling proteins in fibrosis and inflammation, while upregulating the renal protective factor Smad7 in treated animals (Fig. 5).
• In cultured tubular epithelial cells, AZ505 inhibited EMT markers, fibrosis-related proteins, and inflammatory cytokines following cisplatin challenge (Cell culture data).
• AZ505 is widely used to study epigenetic regulation, cancer biology, and the histone methylation pathway, as reviewed in internal resource.

This article extends the mechanistic detail and translational benchmarks presented in AZ505: Potent and Selective SMYD2 Inhibitor for Epigenetic Regulation Research by summarizing peer-reviewed in vivo efficacy and selectivity benchmarks. For practical cell-based workflows and troubleshooting, see AZ505, a Potent and Selective SMYD2 Inhibitor: Real-World...; this article updates with the latest preclinical evidence. For mechanistic perspectives and emerging disease models, compare with AZ505 and the Expanding Frontier of SMYD2 Inhibition: Mechanisms and Models, where this article provides structured, citation-rich summaries.

Applications, Limits & Misconceptions

AZ505 is primarily used in research settings for:

• Epigenetic regulation research, specifically on histone methylation and gene expression.
• Cancer biology research, including studies on gastric cancer and ESCC where SMYD2 is overexpressed.
• Modeling fibrosis and inflammatory diseases, such as chronic kidney disease (CKD).
• Drug discovery and evaluation of substrate-competitive SMYD2 inhibition mechanisms.

Common Pitfalls or Misconceptions

• AZ505 is not suitable for diagnostic or therapeutic use in humans; it is intended for research applications only (APExBIO).
• AZ505 does not inhibit SMYD2 via SAM-competitive mechanisms; it is substrate-competitive.
• Off-target effects are negligible at research-relevant concentrations, but activity at supraphysiological doses (>83.3 μM) against other methyltransferases is not fully characterized.
• Solubility in aqueous buffers is limited; DMSO is required for stock solution preparation.
• AZ505 stability is compromised at room temperature; long-term storage must be at -20°C.

Workflow Integration & Parameters

For in vitro studies, dissolve AZ505 in DMSO to a recommended stock concentration (e.g., 10 mM). Warming to 37°C and ultrasonic shaking improve dissolution. Working concentrations typically range from 0.1–10 μM, depending on the assay. For cell-based assays, ensure final DMSO concentration does not exceed 0.1% v/v. For in vivo studies, consult recent literature for dosing regimens (e.g., 2–5 mg/kg in mouse models). Store stock solutions at -20°C; avoid repeated freeze-thaw cycles. AZ505 is compatible with standard epigenetic assays (e.g., ChIP, methyltransferase activity assays, Western blot for methylation marks) and cell viability assays. For practical troubleshooting and scenario-driven guidance, AZ505, a Potent and Selective SMYD2 Inhibitor: Scenario-Driven Best Practices offers detailed protocols. APExBIO provides the B1255 kit with validated purity and documentation.

Conclusion & Outlook

AZ505 is a validated, potent, and selective SMYD2 inhibitor for research in epigenetic regulation, cancer biology, and fibrotic disease models. Its substrate-competitive mechanism enables targeted dissection of the histone methylation pathway. Peer-reviewed benchmarks confirm robust efficacy and selectivity. Researchers should follow best practices for solubility, storage, and concentration optimization. As the biological roles of SMYD2 expand, AZ505 will remain a critical tool for mechanistic and translational studies. For further reading, consult the APExBIO product page and recent peer-reviewed literature.